

IN THE CLAIMS:

*This listing of claims will replace all prior versions and listings of claims in the application:*

Listing of Claims:

1. (Currently Amended) An isolated monoclonal antibody that specifically binds to human P210 BCR-ABL fusion protein (SEQ ID NO: 1), but does not bind wild type BCR or wild-type c-ABL.
2. (Previously Presented) The antibody of claim 1, wherein said antibody binds a polypeptide comprising residues 94 to 108 of SEQ ID NO: 1.
3. (Previously Presented) The antibody of claim 1, wherein said antibody binds a P210 BCR-ABL polypeptide comprising fusion joint residues 97 to 101 of SEQ ID NO: 1.
4. (Previously Presented) The antibody of claim 1, wherein said antibody specifically detects P210 BCR-ABL fusion protein in a cell-assay selected from the group consisting of flow cytometry (FC), immunohistochemistry (IHC), or immunofluorescence (IF).
5. (Cancelled)
6. (Original) An immortalized cell line producing the antibody of claim 5.
7. (Original) The cell line of claim 6, wherein said cell line is a hybridoma.
8. (Original) The cell line of claim 7, wherein said hybridoma is ATCC Accession No. PTA-5851.
9. (Withdrawn) A method for detecting the presence of P210 BCR-ABL fusion protein in a biological sample, said method comprising the steps of:

(a) contacting a biological sample potentially, or suspected of, containing P210 BCR-ABL fusion protein with at least one antibody of claim 1, under conditions suitable for formation of an anti body-BC R-ABL fusion protein complex; and

(b) detecting the presence of said complex in said biological sample, wherein the presence of said complex indicates the presence of P210 BCR-ABL fusion protein in said sample.

10. (Withdrawn) The method of claim 9, wherein said biological sample is obtained from a subject at risk of, or suspected of, having a disease involving BCR-ABL fusion protein expression.

11. (Withdrawn) The method of claim 10, wherein said disease is chronic myelogenous leukemia (CML).

12. (Withdrawn) The method of claim 9, wherein said biological sample has been contacted with at least one BCR-ABL inhibitor, or is obtained from a subject treated with such inhibitor.

13. (Withdrawn) The method of claim 9, wherein said biological sample has been contacted with a compound being tested for inhibition of BCR-ABL activity or expression.

14. (Withdrawn) A method for identifying a compound that modulates expression of P210 BCR-ABL fusion protein in a biological sample, said method comprising the steps of:

(a) contacting a test biological sample with a test compound,

(b) detecting the level of P210 BCR-ABL fusion protein in said test biological sample of step (a) using at least one antibody of claim 1 under conditions suitable for formation of an antibody-BCR ABL fusion protein complex, and

(c) comparing the level of P210 BCR-ABL fusion protein detected in step (b) with the presence of BCR-ABL fusion protein in a control sample not contacted with said test compound, wherein a difference in P210 BCR-ABL fusion protein levels in said test and control

samples identifies said compound as a compound that modulates expression of P210 BCR-ABL fusion protein.

15. (Previously Presented) A kit for the detection of P210 BCR-ABL fusion protein in a biological sample, said kit comprising at least one detectable antibody of claim 1.